Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Mometasone Furoate · Asmanex, Asmanex Hfa

Small molecule · Agonist of glucocorticoid receptor (NR3C1) · developed by Organon

Approved FDA, May 1987

2 Registered trials

What is Mometasone Furoate?

Mometasone furoate is a corticosteroid with potent anti-inflammatory activity that binds the human glucocorticoid receptor, suppressing inflammatory cells and mediators such as histamine, leukotrienes and cytokines.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Asmanex, Asmanex Hfa, Basic Care Allergy, Nasonex, LYR-210
Drug type: Small molecule
Targets: glucocorticoid receptor (NR3C1)
Mechanism: Agonist of glucocorticoid receptor (NR3C1)
Pathways: inflammatory mediator suppression, anti-inflammatory signaling in mast cells, eosinophils, neutrophils, macrophages
Therapy area: Immunology, Respiratory
Developer: Organon
In trials of: AMRX, ANAB
FDA status: Approved as Asmanex, Asmanex Hfa, Basic Care Allergy (May 6, 1987), NDA019625 · FDA label
UNII: 04201GDN4R

✅ FDA-approved uses

Hay fever or other upper respiratory allergies (temporary relief of nasal congestion, runny nose, sneezing, itchy nose) (Nasonex)
Asthma (Asmanex Hfa)
Hay fever or other upper respiratory allergies (temporary relief of nasal congestion, runny nose, sneezing, itchy nose) (Basic Care Allergy)

From the indications section of the FDA label (version of Aug 19, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02125253	Phase 3	Seasonal Allergic Rhinitis	Completed	AMRX
NCT03614923	Phase 2	Chronic Rhinosinusitis	Completed	ANAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic RhinosinusitisSeasonal Allergic Rhinitis

Other drugs acting on NR3C1

Beclomethasone Dipropionate FDA approved Budesonide FDA approved IDP-118 FDA approved Infacort FDA approved Methylprednisolone FDA approved Mifepristone FDA approved Mometasone FDA approved Relacorilant FDA approved Chronocort Phase 3 Exicorilant Phase 1/2 Miricorilant Phase 2 ORIC-101 Phase 1

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z